Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

681. Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia

Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia Jones MP, Nicholl D, Trakas K CRD summary This review suggested that paliperidone extended-release was an effective and well-tolerated atypical antipsychotic agent in patients with schizophrenia (...) and had a similar profile to some other commonly used atypical antipsychotic agents. Although this review had some limitations with regard to reporting and analysis, the conclusions were consistent with the data presented. Authors' objectives To assess the effectiveness and tolerability of paliperidone extended-release in comparison to other atypical antipsychotic drugs in the management of schizophrenia. Searching MEDLINE, EMBASE, The Cochrane Library, PsycINFO and CINAHL were searched for eligible

2010 DARE.

682. Cognitive remediation therapy in schizophrenia: cost-effectiveness analysis

Cognitive remediation therapy in schizophrenia: cost-effectiveness analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 NHS Economic Evaluation Database.

683. Acetylcholinesterase inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature Full Text available with Trip Pro

Acetylcholinesterase inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature Acetylcholinesterase inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature Acetylcholinesterase inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: a review of the literature Patel SS, Attard A, Jacobsen P, Shergill S CRD summary The authors concluded that there was no direct (...) evidence assessing the use of acetylcholinesterase inhibitors to treat visual hallucinations in patients with schizophrenia. This reflects the findings of the review, but a limited search means that relevant studies might have been missed and the reliability of this conclusion is unclear. Authors' objectives To evaluate the effectiveness of acetylcholinesterase inhibitors in the targeted treatment of visual hallucinations in patients with schizophrenia. Searching MEDLINE and EMBASE were searched

2010 DARE.

684. Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophrenia

Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophrenia Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: ziprasidone is marginally less effective than other atypical antipsychotics in people with schizophrenia Article Text Therapeutics Review: ziprasidone

2010 Evidence-Based Mental Health

685. Review: Is aripiprazole as effective as risperidone in people with schizophrenia?

Review: Is aripiprazole as effective as risperidone in people with schizophrenia? Review: Is aripiprazole as effective as risperidone in people with schizophrenia? | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: Is aripiprazole as effective as risperidone in people with schizophrenia? Article Text Therapeutics Review: Is aripiprazole as effective as risperidone in people with schizophrenia? Statistics from Altmetric.com

2010 Evidence-Based Mental Health

686. Estimates of how many cannabis users need to be prevented in order to prevent one case of schizophrenia

Estimates of how many cannabis users need to be prevented in order to prevent one case of schizophrenia Estimates of how many cannabis users need to be prevented in order to prevent one case of schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Estimates of how many cannabis users need to be prevented in order to prevent one case of schizophrenia Article Text Aetiology Estimates of how many cannabis users need

2010 Evidence-Based Mental Health

687. Review: lack of evidence for the optimal dose of risperidone for schizophrenia

Review: lack of evidence for the optimal dose of risperidone for schizophrenia Review: lack of evidence for the optimal dose of risperidone for schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: lack of evidence for the optimal dose of risperidone for schizophrenia Article Text Therapeutics Review: lack of evidence for the optimal dose of risperidone for schizophrenia Statistics from Altmetric.com Question Question

2010 Evidence-Based Mental Health

688. No differences in mortality and suicide between treated and never-treated people with schizophrenia

No differences in mortality and suicide between treated and never-treated people with schizophrenia No differences in mortality and suicide between treated and never-treated people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here No differences in mortality and suicide between treated and never-treated people with schizophrenia Article Text Therapeutics No differences in mortality and suicide between treated

2010 Evidence-Based Mental Health

689. High- v low-dose quetiapine in schizophrenia: meta-analysis Full Text available with Trip Pro

High- v low-dose quetiapine in schizophrenia: meta-analysis High- v low-dose quetiapine in schizophrenia: meta-analysis High- v low-dose quetiapine in schizophrenia: meta-analysis Painuly N CRD summary The review concluded that high-dose quetiapine was not superior to low doses in the acute treatment of schizophrenia, both in terms of efficacy and effectiveness. In light of the absence of an assessment of trial quality and the limited follow-up periods of the included trials, the author's (...) conclusion should be interpreted with a degree of caution. Authors' objectives To compare the effectiveness of high-dose and low-dose quetiapine in the acute treatment of schizophrenia. Searching PubMed, EMBASE, PsycINFO, AMED, CINHAL and Social SciSearch (SSCI) were searched to August 2007; search terms were reported. References lists of obtained articles were also searched. Study selection Double-blind, randomised controlled trials (RCTs) of the acute treatment of schizophrenia with fixed doses

2010 DARE.

690. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation

The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

691. Atypical antipsychotics for the treatment of schizophrenia: a review of combination therapy and high-dosing strategies

Atypical antipsychotics for the treatment of schizophrenia: a review of combination therapy and high-dosing strategies Atypical antipsychotics for the treatment of schizophrenia: a review of combination therapy and high-dosing strategies Atypical antipsychotics for the treatment of schizophrenia: a review of combination therapy and high-dosing strategies Boucher M, Nkansah E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Boucher M, Nkansah E. Atypical antipsychotics for the treatment of schizophrenia: a review of combination therapy and high-dosing strategies. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions Evidence indicates that adding an AAP to clozapine may be associated with a small to modest improvement in symptom control in patients not adequately responding to optimized

2010 Health Technology Assessment (HTA) Database.

692. Adding aspirin to antipsychotics reduces psychopathology in adults with schizophrenia spectrum disorders Full Text available with Trip Pro

Adding aspirin to antipsychotics reduces psychopathology in adults with schizophrenia spectrum disorders Adding aspirin to antipsychotics reduces psychopathology in adults with schizophrenia spectrum disorders | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adding aspirin to antipsychotics reduces psychopathology in adults with schizophrenia spectrum disorders Article Text Therapeutics Adding aspirin to antipsychotics reduces

2010 Evidence-Based Mental Health

693. Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia Full Text available with Trip Pro

Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia Article Text Therapeutics Review: bupropion increases

2010 Evidence-Based Mental Health

694. Negative symptoms are prevalent in antipsychotic-treated adult outpatients with schizophrenia spectrum disorders

Negative symptoms are prevalent in antipsychotic-treated adult outpatients with schizophrenia spectrum disorders Negative symptoms are prevalent in antipsychotic-treated adult outpatients with schizophrenia spectrum disorders | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Negative symptoms are prevalent in antipsychotic-treated adult outpatients with schizophrenia spectrum disorders Article Text Prevalence Negative symptoms

2010 Evidence-Based Mental Health

695. Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia

Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

696. Schizophrenia and comorbid substance abuse substantially increases risks of violent crime Full Text available with Trip Pro

Schizophrenia and comorbid substance abuse substantially increases risks of violent crime Schizophrenia and comorbid substance abuse substantially increases risks of violent crime | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Schizophrenia and comorbid substance abuse substantially increases risks of violent crime Article Text Aetiology Schizophrenia and comorbid substance abuse substantially increases risks of violent crime Free Hanna

2010 Evidence-Based Mental Health

697. Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia (Abstract)

Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia The authors sought to determine whether prenatal exposure to infection and a positive family history of psychotic disorders interact synergistically to increase the risk of later developing schizophrenia.The authors linked two national registers, the Medical Birth Register and the Finnish Population Register, to identify all women in Helsinki who received hospital (...) and prenatal exposure to infection.Prenatal exposure to infection did not significantly increase the risk of schizophrenia. However, the effect of prenatal exposure to pyelonephritis was five times greater in those who had a family history of psychosis compared to those who did not. The synergy analysis suggested that an estimated 38%-46% of the offspring who developed schizophrenia and had both prenatal exposure to infection and a positive family history of psychotic disorders did so as a result

2009 EvidenceUpdates

698. Monetary incentives for schizophrenia. Full Text available with Trip Pro

Monetary incentives for schizophrenia. There is evidence suggesting that people with serious mental illness are less responsive to everyday social rewards such as praise. Motivation and performance in social situations can be poor. Rewarding of tasks with money improves motivation to complete the tasks in everyday life. Careful use of targeted monetary rewards could also help people with troublesome symptoms of schizophrenia.To assess the effect of monetary incentive/rewards for people (...) with schizophrenia or schizophrenia-like illness.We searched the Cochrane Schizophrenia Group's Register (June 2008).All relevant randomised controlled trials comparing monetary rewards with standard care or no monetary rewards.Working independently, we selected studies for quality assessment and extracted relevant data. We analysed on an intention-to-treat basis. Where possible and appropriate we calculated the Relative Risk (RR) and their 95% confidence intervals (CI). For continuous data we calculated

2009 Cochrane

699. Schizophrenia. (Abstract)

Schizophrenia. Schizophrenia is still one of the most mysterious and costliest mental disorders in terms of human suffering and societal expenditure. Here, we focus on the key developments in biology, epidemiology, and pharmacology of schizophrenia and provide a syndromal framework in which these aspects can be understood together. Symptoms typically emerge in adolescence and early adulthood. The incidence of the disorder varies greatly across places and migrant groups, as do symptoms, course (...) , and treatment response across individuals. Genetic vulnerability is shared in part with bipolar disorder and recent molecular genetic findings also indicate an overlap with developmental disorders such as autism. The diagnosis of schizophrenia is associated with demonstrable alterations in brain structure and changes in dopamine neurotransmission, the latter being directly related to hallucinations and delusions. Pharmacological treatments, which block the dopamine system, are effective for delusions

2009 Lancet

700. Electro-acupuncture versus sham electro-acupuncture for auditory hallucinations in patients with schizophrenia: a randomized controlled trial (Abstract)

Electro-acupuncture versus sham electro-acupuncture for auditory hallucinations in patients with schizophrenia: a randomized controlled trial To compare the efficacy of electro-acupuncture with that of sham electro-acupuncture for auditory hallucinations in patients with schizophrenia partially responsive or non-responsive to risperidone.Patient- and assessor-blinded randomized controlled trial.Hospital-based practice.Schizophrenia patients with auditory hallucinations who are partially (...) at both week 4 and week 6. The clinical response rates in the real electro-acupuncture group and sham electro-acupuncture group were 43.3% (n = 30) and 13.3% (n = 30), respectively (chi(2) = 6.648, P =0.027). There was no significance between-group difference in side-effects.Electro-acupuncture might provide improvement in auditory hallucinations and positive symptom for patients with schizophrenia partially responsive or non-responsive to risperidone monotherapy.

2009 EvidenceUpdates Controlled trial quality: predicted high